Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: Systematic review

British Medical Journal

Volumn 329, Issue 7457, 2004, Pages 75-78

  Lee, Philip E ^a   Gill, Sudeep S ^b   Freedman, Morris ^c   Bronskill, Susan E ^b   Hillmer, Michael P ^d   Rochon, Paula A ^d  

^a ROTMAN RESEARCH INSTITUTE   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d Kunin Lunenfeld Applied Research Unit and Department of Food and Nutrition Services and Baycrest Centre for Geriatric Care   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ALZHEIMER DISEASE; ATAXIA; BEHAVIOR DISORDER; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DATA ANALYSIS; DEMENTIA; DEMOGRAPHY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; HIP FRACTURE; HUMAN; MENTAL DISEASE; PARKINSONISM; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; SYMPTOMATOLOGY;

EID: 3142588866     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.38125.465579.55     Document Type: Review

References (20)

1. Cohen-Mansfield J, Billig N. Agitated behaviours in the elderly. I: a conceptual review. J Am Geriatr Soc 1998;36:7-12.
2. Cohen CA, Gold DP, Shulman KI, Wortley JT, McDonald G, Wargon M. Factors determining the decision to institutionalize dementing individuals: a prospective study. Gerontologist 1993;33:714-20.
3. Schneider LS, Pollock VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990;38: 553-63.
4. Fabbrini G, Barbanti P, Aurilia C. Tardive dyskinesias in the elderly. Int J Geriatr Psychiatry 2001;16:S19-23.
5. Jeste DV, Lacro JP, Bailey A, Rockwell E, Harris MJ, Caligiuri MP. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999;47:716-9.
6. Wirshing WC. Movement disorders associated with neuroleptic treatment. J Clin Psychiatry 2001;62:15-8.
7. Jadad AR, Moore A, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
8. Jüni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001;323:42-6.
9. Brodaty H, Ames D, Snowden J, Woodward M, Kirwan J, Clarnette R, et al. A randomized placebo controlled trial of risperidone for the treatment of aggression, agitation, and psychosis in dementia. J Clin Psychiatry 2003;64:134-43.
10. Chan W, Lam LC, Choy CN, Leung VP, Li S, Chiu HF. A double-blind randomized comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry 2001;16:1156-62.
11. De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PLJ, Eriksson S, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999; 53:946-55.
12. Katz I, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M, et al. Comparison of risperidone and placebo for psychosis and behavioural disturbances associated with dementia: a randomized, double blind trial. J Clin Psychiatry 1999;60:107-15.
13. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU study group. Arch Gen Psychiatry 2000;57:968-76.
14. Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B; Beasley CM Jr, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002;26: 494-504.
15. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatrie inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44, 2308-14.
16. Pwee KH, Shukla VK, Herrmann N, Skidmore B. Novel antipsychotics for agitation in dementia: a systematic review. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2003. (Technology report No 36.)
17. Ballard CG, Margallo-Lana M, Fossey J, Reichelt K, Myint P, Potkins D, et al. A 1-year follow-up study of behavioral and psychological symptoms in dementia among people in care environments. J Clin Psychiatry 2001;62:631-6.
18. Street JS, Clark WS, Kadam DL, Mitan SJ, Juliar BE, Feldman PD, et al. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia. Int J Geriatr Psychiatry 2001;16:S62-70.
19. Davidson M. Long-term safety of risperidone. J Clin Psychiatry 2003; 62:26-8.
20. Buse JB. Metabolic side effects of antipsychotics: focus on hyperglycemia and diabetes. J Clin Psychiatry 2002;63:37-41.